CAMBRIDGE, Mass. — Enveric Biosciences said it has received a new U.S. patent covering methods of treating psychiatric disorders using drug candidates from its EVM301 Series.
The Cambridge-based biotechnology company, which is developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, said the U.S. Patent and Trademark Office issued U.S. Patent No. 12,605,361, titled “Carboxylated Psilocybin Derivatives and Methods of Using.”
The patent, issued April 21, 2026, relates to Enveric’s EVM301 Series of molecules, which are being developed as potential treatments for mental health disorders. The company said the patent includes method claims covering the use of pharmaceutical drug formulations previously patented under U.S. Patent No. 11,752,130.
Enveric said the new patent broadens its intellectual property protection by covering use of novel molecular structures for a family of carboxylated derivatives of tryptamine-based drug candidates.
The company said the patent strengthens its intellectual property portfolio for the EVM301 Series, which includes drug candidates designed to target difficult-to-treat psychiatric conditions.
“Our EVM301 Series continues to develop in strength and breadth with patent protection of potential small molecule therapies designed with the intent to enhance neuroplasticity while reducing or eliminating hallucinations associated with other psychedelic or psychedelic-inspired agents,” said Joseph Tucker, Ph.D., Director and CEO of Enveric Biosciences. “Enveric is focusing its resources on our lead candidate, EB003, to advance our unique molecular design that is intended to achieve a paradigm shift in the treatment of depression and anxiety. Our goal includes offering the opportunity for patients to benefit from psilocybin-derived medications while reducing or eliminating hallucinations otherwise associated with hallucinogenic agents. We anticipate that the potential for a safe and efficacious product that eliminates the requirement for observation by a healthcare professional during dosing will greatly enhance the acceptance and commercial value of EVM301 Series-based therapies and continues to drive Enveric innovation in the field.”
